41 results
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
and operational activities into the first half of 2027.
Research and Development (R&D) Expenses. R&D expenses were $12.4 million for the three month period ended … ,
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense)
Interest
8-K
EX-99.1
ajsc5 bcj23hjdt6
26 Mar 24
Results of Operations and Financial Condition
7:42am
8-K
EX-99.1
7oka1lwan jroqrx
1 Feb 24
Departure of Directors or Certain Officers
7:16am
8-K
EX-99.1
wvl8fxj9hbaslet6m4
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.1
ay20zos
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
424B5
5n02o7qn99u0e9f3
20 Jul 23
Prospectus supplement for primary offering
4:11pm
424B5
0ylmww6kc i38iufj85
17 Jul 23
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
c3iq3scba
9 May 23
Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights
7:08am
PRE 14A
55x6hs6n
14 Apr 23
Preliminary proxy
4:33pm
8-K
EX-99.1
kfkevat2iq98 7r
14 Nov 22
Acumen Pharmaceuticals Reports Third Quarter 2022
4:10pm